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Autoimmune hepatitis (AIH) is an immune- mediated chronic liver disease that affects all ages, including women of 
childbearing age. Optimal management during pregnancy is poorly defined. We aimed to explore the clinical and bio-
chemical course of AIH in the antenatal and postpartum periods, and assess factors associated with premature birth 
and postpartum flares. Pregnant women with AIH reviewed in the autoimmune liver disease clinic at the Queen 
Elizabeth Hospital Birmingham between 2009 and 2020 were identified retrospectively, and clinical, biochemical, and 
immunological data 1  year before conception to 1  year postpartum were collected. Analysis was performed to identify 
trends in blood markers over the antenatal period, with an interrupted time series approach used to assess postpartum 
trends. Data were available for n  =  27 pregnancies (n  =  20 women), with median gestation of 38  weeks (30% prema-
ture) and most having type 1 AIH (78%) and delivering via caesarean section (63%). Levels of alanine transaminase, 
aspartate transaminase, and immunoglobulin G all declined significantly during gestation, followed by significant step- 
change increases after delivery. Postpartum flare developed in 58% of pregnancies. AIH type 2 was associated with a 
higher rate of premature births (67% vs. 19%, P  =  0.044), and a trend toward a higher rate of postpartum flare (100% 
vs. 48%, P  =  0.053). Although not significant, medication nonadherence was associated with almost double the risk 
of prematurity (40% vs. 24%, P  =  0.415) and postpartum flare (80% vs. 44%, P  =  0.109). Conclusion: Biochemical and 
immunological remission of AIH occurs during pregnancy, although subsequent postpartum flare is common. Type 2 
AIH is associated with a higher risk of premature birth and postpartum flare, although further research is required to 
validate and explain this finding. (Hepatology Communications 2021;5:1252-1264).
Autoimmune hepatitis (AIH) is a chronic, immune- mediated, progressive liver dis-ease with variable presentation, ranging 
from asymptomatic to fulminant liver failure.(1) 
Inflammation of the hepatic parenchyma frequently 
evolves toward fibrosis, cirrhosis, and eventually to 
liver failure, exposing patients to the complications of 
cirrhosis and the risk of hepatocellular carcinoma.(2) 
Abbreviations: AIH, autoimmune hepatitis; ALP, alkaline phosphatase; ALT, alanine transaminase; AST, aspartate transaminase; CI, conf idence 
interval; IgG, immunoglobulin G; INR, international normalized ratio; IQR, interquartile range; LKM, liver- kidney- microsome; SLA/LP, soluble 
liver antigen/liver- pancreas; ULN, upper limit of normal.
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AIH has a prevalence of 16- 18 cases per 100,000 in 
Europe, with an increasing incidence.(3) Although it 
is well accepted that breakdown in immune toler-
ance leads to AIH, the pathogenesis of AIH is still 
largely unknown; it appears to occur in genetically 
predisposed individuals, triggered by an environmen-
tal factor.(4)
AIH can affect any age group, including women 
of childbearing age.(2,5) Oligomenorrhea is common 
in patients with active disease or established cirrhosis. 
Nonetheless, many women with well- controlled dis-
ease can conceive and undergo pregnancies without 
complications.(6) With improvements in the quality 
of care of AIH, pregnancies are becoming more fre-
quent.(5,7) The optimal management of AIH during 
pregnancy is an immunosuppressive regimen with 
azathioprine +/- prednisolone, but avoiding mycophe-
nolate, due to its teratogenic effects.(2)
During pregnancy, the course of the disease gener-
ally follows a pattern of remission.(4,7- 9) Mild episodes 
of AIH flares can occur during the first trimester, but 
more severe flares are described postpartum.(7,8,10,11) 
AIH can be associated with an increased risk of 
preterm births, having a low- birth- weight baby, and 
occurrences of liver decompensation during preg-
nancy.(8) Additionally, obstetric risks increase in those 
with liver cirrhosis, with the most commonly observed 
complication being variceal bleeding.(6) Further risk 
factors for pregnancy in AIH have been suggested, 
including the presence of soluble liver antigen/liver- 
pancreas (SLA/LP) and Sjögren’s syndrome– related 
antigen A (Ro/SSA) antibodies, poor disease control 
in the year preceding pregnancy, and an absence of 
immunosuppression during pregnancy.(8,11)
The aims of this study were to assess maternal and 
fetal outcomes in patients with AIH, with a particular 
interest in postpartum flare and premature birth. In 
addition, the study aimed to quantify biochemical and 
immunological changes occurring during the antena-
tal and postpartum periods.
Materials and Methods
This is a retrospective study that included all preg-
nant women with AIH seen in the dedicated autoim-
mune outpatient clinic in the Liver Transplant Unit 
and Center for Rare Disease (European Reference 
Network Rare Liver Center) at Queen Elizabeth 
Hospital Birmingham (England) between January 
2009 and September 2019, with follow- up until July 
2020. The diagnosis of AIH was made on the basis 
of the International Autoimmune Hepatitis Group’s 
simplified criteria.(12) Liver cirrhosis was diagnosed by 
liver biopsy or ultrasound findings. AIH subtype was 
classified based on the presence of associated antibod-
ies; type I AIH is associated with antinuclear antibod-
ies (ANAs) and/or anti- smooth antibodies, and type 
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II AIH with anti- liver- kidney- microsome- 1 (LKM- 
1) antibodies.(1) Patients with overlap syndrome (i.e., 
AIH with primary sclerosing cholangitis or primary 
biliary cholangitis), and pregnancies occurring in 
liver- transplant recipients, were excluded. Only preg-
nancies that resulted in a live birth were included in 
the analysis.
Data relating to patient demographics, disease- 
related factors, preconception medication regimes, 
and pregnancy outcomes were extracted from elec-
tronic patient records, with ethics approval. Premature 
birth was defined as a birth occurring before 37 weeks’ 
gestation. Any evidence of medication nonadher-
ence reported in the electronic patient records were 
also noted, defined as patients stopping medications 
or reducing doses against or without medical advice 
in the year before conception, or during pregnancy. 
Results of blood tests (alanine transaminase [ALT], 
alkaline phosphatase [ALP], aspartate transaminase 
[AST], bilirubin, immunoglobulin G [IgG], albumin, 
and international normalized ratio [INR]) taken as 
part of routine care during the antenatal period (from 
conception to birth) and the postpartum period (from 
birth to 12  months after delivery) were recorded. 
Based on these tests, antenatal/postpartum flares were 
defined based on one of the following criteria, as 
described previously(7,8):
• ALT or AST greater than 2 times the upper limit of 
normal (ULN); or
• ALT or AST greater than 1.5 times ULN and IgG 
greater than 1.5 times ULN and presence of typical 
symptoms of a disease flare (e.g., jaundice, abdomi-
nal pain, fatigue).
In the case of antenatal flares, these criteria had to 
be met between conception and birth; patients who 
already met these criteria before conception required a 
further rise in blood markers to be classified as an an-
tenatal flare. For postpartum flares, the criteria had to 
be met within 12 months after delivery, with patients 
having antenatal flares at the time of delivery requir-
ing a further rise in blood markers to be classified as 
a postpartum flare.
statistiCal analysis
Initially, associations between pregnancy outcomes 
and a range of variables were assessed. Nominal vari-
ables were reported as percentages and analyzed using 
Fisher’s exact test. Continuous variables were reported 
as mean ± SD, or as medians and interquartile ranges 
(IQRs), with comparisons performed using Mann- 
Whitney U tests.
Trends in blood markers over the antenatal period 
were then assessed. Before this analysis, the distribu-
tions of each marker were assessed graphically, with 
log10 transformations applied where positive skew was 
detected. General linear models were then produced, 
with a blood marker set as the dependent variable, 
and the gestation time when the sample was collected 
set as a covariate. The pregnancy ID was additionally 
included as a covariate in the models, allowing each 
pregnancy to have a separate intercept, to account for 
baseline variability. The goodness of fit of the mod-
els was then assessed by examination of the residuals. 
Where poor fit was detected, additional terms were 
added to the model to improve the fit. In models where 
the dependent variable had been log10- transformed, 
the resulting coefficients were then antilogged, and 
converted into percentage changes per month.
Models were then produced to assess postpartum 
trends, and to compare these to the antenatal data, 
using an interrupted time series approach. General 
linear models were produced that contained three 
covariates, the first of which were the pregnancy ID 
and the timing of the sample, relative to delivery. A 
binary factor, stating whether the sample was antenatal 
or postpartum, was also included, to identify any step 
changes occurring directly after delivery. In addition, 
an interaction term between the timing of the sample 
and the variable stating whether it was collected in 
the antenatal or postpartum period was also added to 
the model. This allowed for separate gradients in the 
antenatal and postpartum periods, and produced a P 
value comparing them. All analyses were performed 
using IBM SPSS 22 (IBM Corp., Armonk, NY), 




After excluding one still birth and two miscar-
riages, 27 pregnancies in 20 women were included in 
the study, with 5 women contributing two pregnancies 
and 1 woman contributing three pregnancies to the 
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cohort. The analysis was performed at a pregnancy 
level, and demographics of the cohort are reported 
in Tables 1 and 2. The mean age at conception was 
29 years, and most of the cohort was of White ethnic-
ity (63%). Twenty- one pregnancies (78%) occurred in 
women with type 1 AIH, with the remaining 6 (22%) 
in women with type 2 AIH; conception was a median 
of 6  years after AIH diagnosis. Twelve pregnancies 
(44%) occurred in women with cirrhosis, 10 (37%) in 
women with fibrosis, and 5 (19%) in women with no 
fibrosis or cirrhosis. Most of the pregnancies occurred 
in the absence of additional autoimmune conditions. 
Where patients did have additional autoimmune con-
ditions, these were type 1 diabetes mellitus, systemic 
lupus erythematosus, celiac disease, alopecia, and 
immune thrombocytopenia.  ANAs were present in 
56% of pregnancies, anti- smooth muscle antibodies 
in 52%, and Ro- 52 antibodies in 50% (not mutually 
exclusive).
meDiCations
Most women were taking dual (52%) or sin-
gle (37%) immunosuppression before conception, of 
which prednisolone (59%) and/or azathioprine (67%) 
were the most commonly used agents (Table 1). One 
unplanned pregnancy occurred while taking mycophe-
nolate, which was subsequently stopped at 10  weeks’ 
gestation; no maternal or neonatal complications were 
noted. One woman had received a rituximab infusion 
6  months before conception; this pregnancy ended 
with a neonatal complication of jaundice requiring 
ultraviolet therapy. Issues regarding immunosup-
pression nonadherence were identified in 10 (37%) 
pregnancies.
antenatal suRVeillanCe oF 
CiRRHosis
Of the 12 pregnancies occurring in women with 
liver cirrhosis, 9 (75%) underwent oesophageal- 
gastro- duodenoscopy (OGD), 5 of which found no 
evidence of varices, whilst 1 showed evidence of por-
tal hypertensive gastropathy with no bleeding, and 
3 demonstrated varices that required banding. Liver 
ultrasound was performed in 10 pregnancies (83%), 
none of which found any evidence of splenic artery 
aneurysms. Four pregnancies (33%) for which caesar-
ean sections were being considered underwent pelvic 
taBle 1. DemogRapHiCs oF tHe CoHoRt
Total (n) Statistic
Age at conception (years) 27 29 ± 5
Ethnicity (% White) 27 17 (63%)
Twin pregnancy 27 1 (4%)
Previous pregnancies 27
None 14 (52%)
1- 2 9 (33%)
>2 4 (15%)




Diabetes before pregnancy 27
No 23 (85%)
Type 1 2 (7%)
Type 2 (steroid induced) 2 (7%)
AIH diagnosis to conception (years) 27 6 (3- 10)
AIH type 27
Type 1 21 (78%)
Type 2 6 (22%)
Associated autoimmune disease† 27 7 (26%)
Fibrosis/cirrhosis 27
None 5 (19%)
Mild fibrosis 2 (7%)
Moderate fibrosis 7 (26%)





No immunosuppression 2 (7%)
Single immunosuppression 10 (37%)
Dual immunosuppression 14 (52%)
Triple immunosuppression 1 (4%)
Prepregnancy immunosuppression 
agents
Azathioprine 27 18 (67%)
Prednisolone 27 16 (59%)
UDCA 27 3 (11%)
Mercaptopurine 27 3 (11%)
Budesonide 27 2 (7%)
Mycophenolate‡ 27 1 (4%)
Tacrolimus 27 1 (4%)
Rituximab§ 27 1 (4%)
Medication nonadherence 27 10 (37%)






Anti- smooth muscle antibodies  
(% positive)
27 14 (52%)
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magnetic resonance imaging, none of which found 
evidence of pelvic varices.
pRegnanCy outComes
The median gestation at delivery was 38  weeks 
(IQR 36- 39), with 30% ending in premature births 
(Table 3). Data regarding delivery method were avail-
able for n = 24 pregnancies, of which most of the deliv-
eries were via caesarean section (63%). Pregnancies 
with cirrhosis were delivered via caesarean section in 
73% (8 of 11) of cases, pregnancies with fibrosis in 
33% (3 of 9), and pregnancies without cirrhosis or 
fibrosis in 100% (4 of 4). From our records, it was not 
possible to discern whether the caesarean sections had 
been performed due to patient choice or clinical need.
The most commonly recorded maternal compli-
cation was cholestasis of pregnancy (15%), while the 
most common neonatal complication was fetal dis-
tress (7%). It was not possible to ascertain whether an 
antenatal flare occurred during two pregnancies, due 
to a lack of available blood tests. Of the remainder, an 
antenatal flare occurred during 12% of pregnancies (3 
of 25), all of which also experienced a postpartum flare, 
and two had concerns about medication adherence 
noted. We were not able to carry out a full statistical 
analysis of antenatal flares due to the low incidence. 
Postpartum blood tests were unavailable for one preg-
nancy; hence, it could not be ascertained whether a 
postpartum flare had occurred. Of the remainder, 58% 
(15 of 26) developed a postpartum flare.
Associations between patient factors and the pri-
mary pregnancy outcomes of premature birth and 
postpartum flare were then assessed (Table 4). These 
analyses had low statistical power on account of 
the small sample size; hence, only large effects were 
detectable. Despite this, pregnancies in women with 
AIH type 2 were found to have a significantly higher 
rate of premature births than those with type 1 dis-
ease (67% vs. 19%, P = 0.044), with a near- significant 
tendency for a higher rate of postpartum flare also 
observed (100% vs. 48%, P  =  0.053). Additionally, 
although not significant, there was almost double 
the risk of prematurity (40% vs. 24%, P = 0.415) and 
postpartum flare (80% vs. 44%, P  =  0.109) in preg-
nancies with issues surrounding medication nonad-
herence. The single patient with a twin pregnancy had 
developed a severe postpartum flare, with an ALT of 
758 U/L and bilirubin of 102 µmol/L.
tRenDs in alt anD igg
A total of n  =  71 antenatal blood tests were per-
formed in n = 25 pregnancies, with a median of three 
tests per pregnancy (range: 1- 5). In addition to the 
antenatal samples, n = 107 samples were collected from 
n = 26 of the pregnancies over the postpartum period, 
with a median of four per pregnancy (range: 1- 11). In 
each case, data were not available for all markers from 
each blood test. Initially, models were produced using 
only data from the antenatal period (Table 5 and 
Fig. 1); these were then extended to include postpar-
tum samples (Table 6 and Fig. 2), to allow compari-
sons between the two periods.
During the antenatal period, markers of disease 
activity were found to decline significantly, with ALT 
decreasing by an average of 13.3% per month (95% 
confidence interval [CI]: 9.4%- 17.1%, P  <  0.001) 
and IgG by 4.9% per month (95% CI: 3.4%- 6.4%, 
P < 0.001). After delivery, both markers saw a signif-
icant step- change increase, with ALT levels tripling 
(205.7% increase, 95% CI: 103.3%- 359.6%, P < 0.001) 
and IgG increasing by 39.4% (95% CI: 25.2%- 55.2%, 
P < 0.001). Both markers then remained relatively sta-
ble for the 12 months postpartum, with no significant 
gradient detected in either ALT (P  =  0.219) or IgG 
(P = 0.141).
tRenDs in otHeR BiomaRKeRs
Similar significant antenatal declines were also 
observed in albumin, AST, bilirubin, and INR (all 
Total (n) Statistic
LC- 1 antibodies (% positive) 24 1 (4%)
SLA/LP antibodies (% positive) 24 7 (29%)
Ro- 52 antibodies (% positive) 12 6 (50%)
f- actin antibodies (% Positive) 12 2 (17%)
LKM blot (% positive) 24 6 (25%)
LKM antibodies (% positive) 26 5 (19%)
Note: Data are reported as n (%), median (IQR), or mean ± SD, as 
applicable.
*For the subgroup of patients with previous pregnancies.
†Other than type 1 diabetes mellitus.
‡Stopped at 10 weeks’ gestation.
§Given as a one- off dose in the 6 months before conception.
Abbreviations: f- actin, filamentous actin; and LC- 1, liver cytosol 
antigen type- 1; UDCA, ursodeoxycholic acid.
taBle 1. Continued
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P  <  0.001; Table 5 and Fig. 1). The initial model of 
ALP found levels to increase significantly over the 
antenatal period (P  <  0.001). However, this model 
was found to have suboptimal fit, and so the analysis 
was repeated with a quadratic model, which is visu-
alized in Fig. 1G. This found ALP levels to decline 
early in the pregnancy, reaching a trough at approx-
imately 4 months gestation, after which levels began 
to increase.
After delivery, significant step- change increases were 
observed in albumin (P  <  0.001), AST (P  =  0.045), 
bilirubin (P = 0.013), and INR (P = 0.012). No signif-
icant step change was observed for ALP (P = 0.136), 
with this marker instead showing an inverted 
“V- shaped” trend, increasing by 8.8% per month (95% 
CI: 6.2%- 11.6%, P  <  0.001) in the antenatal period, 
before this reversed to a 3.7% per month decline 
(95% CI: 2.1%- 5.3%, P  <  0.001) in the postpartum 
period. INR also showed a “V- shaped” trend, with the 
gradient changing from a 0.012 per month decline 
(95% CI: 0.006- 0.017, P  <  0.001) to a 0.005 per 
month increase (95% CI: 0.002- 0.009, P  =  0.006) 
between the two periods.
BlooD maRKeRs in Repeat 
pRegnanCies
The n  =  6 women with data from multiple preg-
nancies were then further assessed. Of these, two had 
additional pregnancies before the study period, for 
which data were not available. Of the 3 women who 
had postpartum flares in their first pregnancy during 
the study period, 2 (66%) had a flare in their sec-
ond pregnancy. For the 3 without a postpartum flare 
in their first pregnancy, 2 (66%) had a flare in their 
second pregnancy. Figure 3 shows the trajectories of 
IgG, ALT, and bilirubin for the n  =  5 patients who 
had samples from both the antenatal and postpartum 
periods.
Discussion
With the improvement of multidisciplinary care 
among hepatologists, obstetricians, and clinical nurse 
specialists in AIH, pregnancy is becoming increas-
ingly common in patients with this rare disease.(5,7)
Using an interrupted time- series approach, we 
have shown that during pregnancies in women with 
AIH, ALT and IgG decline significantly with ges-
tation, followed by a significant step- change increase 
immediately after delivery. Remission of AIH during 
pregnancy is well documented, having been reported 
in several previous studies.(4,8- 10) Despite the course 
of the disease appearing to enter a period of remis-
sion during pregnancy, cases of flare during the ges-
tation period have been reported.(13) The incidence 
of postpartum flares in AIH has been described in 
13% to 52% of pregnancies.(7,8,10,11,13) In accordance 
with previous case series, in our cohort, pregnancy was 
associated with reductions in disease activity in most 
cases, with antenatal flares in disease activity occur-
ring in only 12% of cases. This was followed by a high 
incidence of postpartum flares, which occurred in over 
half of the pregnancies. For the subgroup of women 
with multiple pregnancies, blood markers appeared to 
follow similar trends across all pregnancies. However, 
due to the limited quantity of data in this sub-




Caesarean section 15 (63%)
Vaginal 9 (38%)
Gestation at delivery (weeks) 27 38 (36- 39)
Premature birth 27 8 (30%)
Any pregnancy complication* 27 14 (52%)
Maternal complications† 27
Cholestasis of pregnancy 4 (15%)
Gestational diabetes, new onset 2 (7%)
Gestation diabetes, worsening 1 (4%)
Hypertension of pregnancy 1 (4%)




Peripartum renal failure 1 (4%)
Neonatal complications† 27
Fetal distress 2 (7%)
Jaundice 1 (4%)
Reduced fetal heartbeat 1 (4%)
Growth retardation 1 (4%)
Extended neonatal unit stay 1 (4%)
Antenatal flare 25 3 (12%)
Postpartum flare 26 15 (58%)
Note: Data are reported as n (%) or median (IQR), as applicable.
*Pregnancies in which any of the listed maternal or neonatal 
complications occurred.
†Not mutually exclusive.
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studies, would be warranted to quantify the associa-
tions between disease activity in repeated pregnancies.
We did not confirm the association between the 
presence of SLA/LP and Ro/SSA antibodies and 
adverse pregnancy outcomes in AIH, as found in a 
previous study.(11) However, our data show for the 
first time a correlation between type 2 AIH and post-
partum flares. Recently, the subclassification of AIH 
into type 1 and type 2 has been debated, because it 
fails to discriminate phenotypic and prognostic dif-
ferences.(14) Despite this, it is well accepted that type 
2 AIH has a more aggressive onset in children, with 
a high rate of fulminant hepatitis.(15) Data on long- 
term outcomes in these patients are currently lacking, 
due to the difficulty in maintaining follow- up after 
taBle 4. assoCiations WitH pRegnanCy 
outComes
Premature Birth Postpartum Flare
Age at conception 
(years)
P = 0.076* P = 0.375*
<30 43% (6 of 14) 69% (9 of 13)
30+ 15% (2 of 13) 46% (6 of 13)
Ethnicity P = 1.000 P = 0.109
White 29% (5 of 17) 44% (7 of 16)




No 29% (4 of 14) 46% (6 of 13)
Yes 31% (4 of 13) 69% (9 of 13)




<6 25% (3/12) 58% (7/12)
6+ 33% (5/15) 57% (8/14)
AIH type P = 0.044 P = 0.053
Type 1 19% (4 of 21) 48% (10 of 21)




No 35% (7 of 20) 53% (10 of 19)
Yes 14% (1 of 7) 71% (5 of 7)
Fibrosis/cirrhosis P = 0.643 P = 0.342
No 40% (2 of 5) 60% (3 of 5)
Fibrosis 20% (2 of 10) 40% (4 of 10)
Cirrhosis 33% (4 of 12) 73% (8 of 11)
ANA P = 0.087 P = 0.701
Negative 50% (6 of 12) 64% (7 of 11)
Positive 13% (2 of 15) 53% (8 of 15)
Anti- smooth muscle 
antibody
P = 0.420 P = 1.000
Negative 38% (5 of 13) 58% (7 of 12)
Positive 21% (3 of 14) 57% (8 of 14)
SLA/LP antibodies P = 0.374 P = 1.000
Negative 24% (4 of 17) 65% (11 of 17)
Positive 43% (3 of 7) 57% (4 of 7)
Ro- 52 antibodies P = 1.000 P = 1.000
Negative 33% (2 of 6) 50% (3 of 6)
Positive 33% (2 of 6) 50% (3 of 6)
LKM blot P = 1.000 P = 0.351
Negative 28% (5 of 18) 56% (10 of 18)
Positive 33% (2 of 6) 83% (5 of 6)
LKM antibodies P = 0.281 P = 0.125
Negative 24% (5 of 21) 52% (11 of 21)




No 24% (4 of 17) 44% (7 of 16)
Yes 40% (4 of 10) 80% (8 of 10)
 





None/single 25% (3 of 12) 50% (6 of 12)
Dual/triple 33% (5 of 15) 64% (9 of 14)
Note: Data are reported as % (n), and P values are from Fisher’s 
exact tests, unless stated otherwise. Bold P values indicate signifi-
cance at P < 0.05.
*P values from Mann- Whitney U tests, comparing the exact num-
bers of years between those with versus without outcomes.
†Other than type 1 diabetes mellitus.
Abbreviations: LC- 1, liver cytosol antigen type 1; f- actin, filamen-
tous actin.
taBle 4. ContinueD




Gradient per Month 
(95% CI) P Value
Albumin (g/L) 70 −1.52 (−1.72, −1.31) <0.001
ALP (U/L)* 70 9.2% (6.4%, 12.0%) <0.001
ALT (U/L)* 69 −13.3% (−17.1%, 9.4%) <0.001
AST (U/L)* 53 −8.9% (−12.4%, −5.3%) <0.001
Bilirubin (umol/L)* 69 −6.2% (−9.0%, −3.2%) <0.001
INR 60 −0.012 (−0.018, −0.006) <0.001
IgG (g/L)* 48 −4.9% (−6.4%, −3.4%) <0.001
Note: Results are from general linear models with the pregnancy 
ID and gestation of the sample as covariates. Bold P values indicate 
significance at P < 0.05.
*Blood markers followed skewed distributions, and therefore log10- 
transformed before the analysis. The resulting coefficients were 
then antilogged and converted into percentage changes per month.
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Fig. 1. Trends in blood markers over the antenatal period. Solid lines represent individual pregnancy trajectories. Broken black lines are 
trends for the cohort as a whole and are derived from the models reported in Table 5. The y axes use logarithmic scales for all markers, 
except for albumin and INR, to improve scaling. The plot of ALP includes an additional broken red line, which is based on a polynomial 
model that includes a gestation- squared term. (A) trends in albumin (g/L), (B) trends in ALT (U/L), (C) trends in AST (U/L), (D) trends 
in bilirubin (umol/L), (E) trends in INR, (F) trends in IgG (g/L), (G) trends in ALP (U/L).
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transition to adult care. Our data suggest that there is 
an augmented risk of disease relapse after pregnancy 
in patients with type 2 AIH, although this did not 
reach statistical significance, meaning that further 
multicenter studies would be required to confirm this 
finding. A significantly increased rate of preterm birth 
was also observed in patients with type 2 AIH. The 
evaluation of miscarriage and stillbirth was beyond 
the scope of our study. Nonetheless, it would be inter-
esting to evaluate the rate of pregnancy related out-
comes in patients with type 2 AIH.
Nonadherence with medications was a concern in 
37% of pregnancies in our cohort. Although issues 
surrounding medication adherence in AIH have been 
reported in children,(16) patients with AIH gener-
ally report their medication adherence as “good.”(17) 
Concerns regarding adherence have previously been 
reported among patients with other long- term condi-
tions during pregnancy, reporting rates similar to our 
findings, with 36.2% of patients having low adherence 
to medication regimes.(18) We found that there was 
a trend toward more premature births (40% vs. 24%) 
Fig. 2. Trends in blood markers in the antenatal versus postpartum periods. The horizontal line represents the point of delivery; hence, 
the antenatal period is to the left, and the postpartum period is to the right. Points represent the arithmetic or geometric mean of all 
samples taken within each three monthly interval, and are plotted at the midpoint of the interval. Error bars indicate 95% CIs. Broken 
lines are derived from the models reported in Table 6. (A) trends in albumin (g/L), (B) trends in ALT (U/L), (C) trends in AST (U/L), 
(D) trends in bilirubin (umol/L), (E) trends in INR, (F) trends in IgG (g/L), (G) trends in ALP (U/L).
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and postpartum flares (80% vs. 44%) in pregnancies 
in which medication adherence was an issue, although 
neither of these differences reached statistical signif-
icance. Additionally, 66% of antenatal flares occurred 
in pregnancies with medication- adherence concerns. 
An exploration of the attitudes of women with AIH 
regarding the use of immunosuppression during preg-
nancy would be useful, to fully understand why there 
are issues with adherence, and how to devise strategies 
to overcome them.
Twelve of the pregnancies in our study occurred in 
the presence of liver cirrhosis, which has previously 
been shown to increase obstetric risks.(6) One serious 
complication is variceal bleeding, occurring from 
the second trimester onward, and during labor.(6,19) 
Variceal bleeding carries a high rate of mortality and 
morbidity in the context of liver cirrhosis.(6) Most 
of our patients with cirrhosis underwent OGD for 
variceal surveillance, and, importantly, none of our 
patients experienced any instances of variceal bleed-
ing during pregnancy or labor. In our study, patients 
with cirrhosis underwent caesarean section in 73% of 
pregnancies. This is higher than the average rate for 
Europe(20); however, it has previously been reported 
that patients with liver cirrhosis have higher rates of 
caesarean sections.(21,22) In patients with cirrhosis, the 
Fig. 3. Trends in blood markers for patients with repeat pregnancies. Each plot represents a single patient, with data for all pregnancies 
included in the cohort. One patient with multiple pregnancies was excluded, as she had no antenatal samples. (A) trends in ALT (U/L), 
(B) trends in IgG (g/L), (C) bilirubin (umol/L).
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choice of delivery method should be based on obstet-
ric indications, as there is limited evidence to recom-
mend a preferred method with these patients.(23)
Our study suffers from being a retrospective and rela-
tively small study, with potential selection bias and miss-
ing data confounding the analysis. The small sample size 
resulted in low statistical power, particularly when ana-
lyzing associations with pregnancy outcomes (postpar-
tum flare and premature birth). Additionally, we did not 
include miscarriages and stillbirths, as the numbers of 
these were small and, hence, it was not possible to com-
pare these to pregnancies ending in live births. However, 
there may be a difference in blood marker trends among 
live births, stillbirths and miscarriages, and this is a topic 
that we would like to explore in the future.
In conclusion, biochemical and immunologi-
cal remission of AIH occurs during pregnancy, with 
albumin, ALT, AST, bilirubin, and IgG declining sig-
nificantly as gestation progresses. Postpartum flare is 
common in AIH, with ALT and IgG showing signif-
icant step- change increases after delivery.
The risk of both premature birth and postpartum 
flare appears to be higher in type 2 AIH and may be 
increased in patients with nonadherence to medica-
tion. Multidisciplinary care between the obstetric and 
liver teams with regular meetings to discuss mater-
nal and fetal progress is crucial for the management 
of pregnant patients with AIH. As twin pregnancy 
was associated with a severe flare- up of AIH, these 
patients should be monitored closely in the post-
partum period. Exploration of the immunological 
mechanism of remission of AIH during pregnancy 
and immune tolerance breakdown during the post-
partum period with both blood and placental tissue 
is warranted, to predict and prevent postpartum flare. 
Further evaluation of the attitudes of patients with 
AIH toward the importance of medication adher-
ence of immunosuppression during pregnancy can be 
addressed during prepregnancy counseling.
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